We are in Glasgow for @theEBMT 50th Annual Meeting and to recognize five decades of scientific exchange and innovation from the #celltherapy community. We look forward to discussions on how we can change the future for people living with blood cancers. #EBMT24

As the only company dedicated solely to the research, development and manufacturing of #celltherapy , we are pleased to announce we are approved to make our treatment available in Brazil, Saudi Arabia and Singapore.

Kite has embedded sustainability into our culture and global manufacturing operations. Our collaboration with Sustainability Magazine shares how we ensure we are having a positive impact on the communities where we live and work.

Read more: bit.ly/49DPJRQ

We’re looking forward to attending the 6th European CAR T-cell Meeting where the newest advancements in #celltherapy are discussed, including our research. #CART24

#InTheNews : We’re proud to be part of Gilead Sciences.

#KiteNews : The U.S. FDA has approved a manufacturing process change resulting in a shorter manufacturing time for our #celltherapy , which is anticipated to reduce median turnaround time from 16 to 14 days in the United States.

Read more: bit.ly/42hzUxk

#KiteNews : The U.S. FDA has approved a label update for our CAR T-cell therapy to include overall survival data from a primary analysis of our therapy versus standard of care as second-line treatment with curative intent.

Read more: bit.ly/41zskhh

#KiteNews : Today, we shared analyses of three #CARTcell therapy studies that explore curative potential for patients living with several sub-types of R/R non-Hodgkin lymphoma at ASH's Annual Meeting. #ASH23  
 
Read more: bit.ly/3NmScXK

#KiteNews : Today, we announced four new long-term follow-up analyses that support the use of #celltherapy for the treatment of R/R mantle cell lymphoma and R/R adult B-cell precursor acute lymphoblastic leukemia at #ASH23 .  
   
Read more: bit.ly/3RNuKpj

#KiteNews : Announcing new findings from a follow-up analysis of #CARTcell therapy from the first study of its kind in patients with high-risk, large B-cell lymphoma. The study’s results were presented at #ASH23  .
 
Read more: bit.ly/4agtqlF

We’re pleased to share that our partner @Arcellx will present new data in relapsed/refractory multiple myeloma at ASH's Annual Meeting. #ASH23

Ahead of #ASH23 , hear from Kite’s Global Head of Clinical Development Frank Neumann, MD, PhD, and Global Head of Research Priti Hegde, PhD, on how far the science of cell therapy has progressed and where it is headed.

#KiteNews : Together with Gilead Oncology, we’ll share 29 presentations across our blood cancer portfolio at @ASH_Hematology’s Annual Meeting. #ASH23

Read more: bit.ly/3FGtXzl

#KiteNews : Today, we announced that we’ve entered into a research collaboration and license agreement with Epic Bio using their proprietary gene regulation platform to develop next-generation cancer cell therapies.

Learn more: bit.ly/40ixJs9 #celltherapy

#KiteNews : Together with Gilead Oncology, we will present data from our oncology portfolio at #ESMO23 , including new #celltherapy research. @MyESMO

Read more: bit.ly/401odcP

This week, we announced Priti Hegde, PhD, will join Kite as Senior Vice President and Global Head of Research. bit.ly/3Q58WnV

Today, we announced full results from a Phase 2 study led by the French collaborative group LYSA/LYSARC for CAR T-cell therapy as a second-line treatment for transplant ineligible patients with large B-cell #lymphoma , published in Nature Medicine

Advances in #celltherapy offer the potential for more treatment options for patients battling cancer. This is our sole focus – researching, manufacturing, and commercializing innovative treatment options to reach as many eligible patients as possible who may benefit from them.

We’re proud to join Gilead Oncology to serve as the National Presenting Sponsor of Celebration and Community for #LightTheNight 2023. Together with the The Leukemia & Lymphoma Society, we’re shining a light on the darkness of cancer. Here’s a look at last year’s event.